Pharming (PHAR) Revenue (2020 - 2026)

Pharming (PHAR) has 7 years of Revenue data on file, last reported at $162.7 million in Q2 2026.

• Quarterly Revenue rose 94396789.42% year-over-year to $162.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $366.5 million (up 363.32% YoY) and the FY2025 annual result came in at $376.1 million, up 26.56% from the prior year.
• Revenue climbed to $162.7 million in Q2 2026, from $0.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $54900.0 billion in Q2 2023 to a low of $0.0 in Q1 2026.
• A 5-year average of $3050.1 billion and a median of $54.9 million in 2022 frame the typical range for Revenue.
• Annual changes were most pronounced in 2025 — Revenue jumped 130080113.9% — and 2026, when it slumped 100.0%.
• Tracing PHAR's Revenue over 5 years: stood at $151.0 million in 2022, then sank by 100.0% to $81.2 in 2023, then soared by 151.85% to $204.5 in 2024, then surged by 52078139.61% to $106.5 million in 2025, then surged by 52.73% to $162.7 million in 2026.
• The last three Revenue figures came in at $162.7 million (Q2 2026), $0.0 (Q1 2026), and $106.5 million (Q4 2025), per Business Quant data.